Journal of Breast Cancer最新文献

{"title":"Body Composition Changes Induced by Perioperative Chemotherapy in Patients With Breast Cancer.","authors":"Woochan Park, Changhee Park, Jinyong Kim, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im","doi":"10.4048/jbc.2026.0104","DOIUrl":"https://doi.org/10.4048/jbc.2026.0104","url":null,"abstract":"<p><strong>Purpose: </strong>Fluid retention is a well-recognized adverse effect of docetaxel; however, its impact on body composition has rarely been characterized longitudinally. Herein, we describe serial changes in body composition, including body water compartments, throughout the different phases of perioperative chemotherapy for breast cancer.</p><p><strong>Methods: </strong>Patients receiving neoadjuvant or adjuvant chemotherapy containing docetaxel, either doxorubicin plus cyclophosphamide (AC) followed by sequential docetaxel or docetaxel plus cyclophosphamide (TC), underwent bioelectrical impedance analysis before every cycle. The AC, sequential docetaxel, and TC phases were analyzed by comparison with their respective baselines using paired <i>t</i>-tests. Hydration indices, including extracellular water (ECW)/total body water (TBW), TBW/fat-free mass, and extracellular mass/body cell mass, were used to differentiate fluid-related changes from tissue-related changes, with measurements obtained before the docetaxel phase considered the pre-chemotherapy baseline.</p><p><strong>Results: </strong>Sixty-one patients were enrolled, and 367 measurements were analyzed. During AC, TBW, intracellular water (ICW), and lean-mass indices decreased, whereas fat mass increased and body weight remained unchanged. During sequential docetaxel, increases in water compartments and lean indices were accompanied by increases in hydration indices (all <i>p</i> < 0.001 before cycle 4), indicating extracellular fluid expansion. Relative to the pre-chemotherapy baseline, rather than the post-AC nadir, lean indices and ICW returned to approximately pretreatment values but did not exceed them, whereas ECW rose above it (+0.34 L, <i>p</i> = 0.013). No parameter changed significantly during TC.</p><p><strong>Conclusion: </strong>Perioperative chemotherapy resulted in regimen-specific changes in body composition. During AC, body water and lean mass decreased, and fat mass increased, despite a stable body weight. The apparent increase in lean mass during sequential docetaxel treatment was better explained by recovery from the post-AC nadir accompanied by extracellular fluid accumulation than by true muscle gain. Therefore, body weight alone may be insufficient for monitoring these changes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Breast Pure Metaplastic Squamous Cell Carcinoma: A Breast Abscess With Squamous Metaplasia and Malignant Transformation That Mimics Condylomata Acuminata.","authors":"Jing Wen Loh, Ai Chen Chan, Bin Abd Rashid Khairi Abdul Kadir Rifaei, Abu Bakar Najihah","doi":"10.4048/jbc.2026.0091","DOIUrl":"https://doi.org/10.4048/jbc.2026.0091","url":null,"abstract":"<p><p>Pure metaplastic squamous cell carcinomas (MSCC) of the breast are rare. We report the case of a 57-year-old woman who presented with a breast abscess in whom a papillomatous lesion was identified during incision and drainage. The initial biopsy demonstrated hyperplastic squamous epithelium with koilocytic atypia, raising the possibility of condylomata acuminata. Subsequent wide excision revealed extensive squamous metaplasia with invasive squamous cell carcinoma arising within a cystic papillary lesion consistent with pure MSCC of the breast. Immunohistochemistry revealed positivity for p63 and negativity for p16, estrogen receptor, progesterone receptor, and human epidermal growth receptor 2. The investigations excluded human papillomavirus infections, cutaneous origins, and extramammary primary squamous cell carcinomas. Following early local recurrence, the patient underwent mastectomy and axillary dissection. Adjuvant radiotherapy and chemotherapy were also administered. This case highlights the diagnostic challenges and aggressive behavior of pure MSCC and emphasizes the importance of clinicopathological correlations and multidisciplinary management.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poly(ADP-ribose) Polymerase Inhibitor Talazoparib Inhibits DNA Damage Repair in Breast Cancer Cell Lines With or Without <i>BRCA1/2</i> Mutation.","authors":"Miso Lee, Kyung-Hun Lee, Ahrum Min, Sujin Ham, Jihyeon Moon, Yu-Jin Kim, Hae Min Hwang, Youlim Noh, Eunice Yoojin Lee, Hye Yeon Park, Jiwon Koh, Changhee Park, Dae-Won Lee, Seock-Ah Im","doi":"10.4048/jbc.2026.0085","DOIUrl":"https://doi.org/10.4048/jbc.2026.0085","url":null,"abstract":"<p><strong>Purpose: </strong>Talazoparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. Although PARP inhibitor sensitivity has traditionally been attributed to synthetic lethality in tumors with BRCA1/2 mutations or homologous recombination repair deficiency, emerging evidence indicates that clinical and preclinical activity may extend to selected tumors beyond those harboring germline BRCA1/2 mutations. This study investigated the mechanism underlying talazoparib efficacy in both <i>BRCA1</i>/2-mutant and <i>BRCA1</i>/2 wild-type breast cancer cells.</p><p><strong>Methods: </strong>Twenty-one breast cancer cell lines, including both <i>BRCA-1</i>/2-mutant and wild-type cells, were treated with talazoparib, and the effects of the treatment on cell proliferation, cell cycle progression, DNA damage accumulation, and apoptosis were evaluated.</p><p><strong>Results: </strong>Talazoparib demonstrated antiproliferative effects in <i>BRCA1</i>/2-mutant and wild-type cells in a long-term culture system, as assessed by colony formation assays. Accumulation of single-stranded and double-stranded DNA damage was observed in talazoparib-sensitive cell lines, as indicated by phosphorylated RPA and γ-H2AX, respectively. This was accompanied by G2/M arrest and subsequent apoptosis, as evidenced by cleaved caspase-3 expression and Annexin V staining. Abnormal mitotic nuclei were observed in talazoparib-sensitive cell lines, which also exhibited potent and sustained PARP1 trapping on chromatin.</p><p><strong>Conclusion: </strong>Talazoparib exerts anti-tumor effects in <i>BRCA1</i>/2-mutant and wild-type breast cancer cells by promoting the formation of abnormal mitotic nuclei and inducing apoptosis in sensitive cells. Our findings support the potential therapeutic application of talazoparib beyond its current indications for <i>BRCA1/2</i>-mutant tumors.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Letter to the Editor: Diet and Breast Cancer Survivorship: A Scoping Review\".","authors":"Hyun Jeong Cho, Amber Hsiao, Akinkunmi Okekunle, Jung Eun Lee","doi":"10.4048/jbc.2026.0203","DOIUrl":"https://doi.org/10.4048/jbc.2026.0203","url":null,"abstract":"","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: \"Diet and Breast Cancer Survivorship: A Scoping Review\".","authors":"Muhammed Said Aydin, Gökay Özler, Cansu Aydin, Sedef Ayşe Ceylan","doi":"10.4048/jbc.2026.0165","DOIUrl":"https://doi.org/10.4048/jbc.2026.0165","url":null,"abstract":"","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Outcomes of Acellular Dermal Matrix Use in Breast-Conserving Surgery: A Single-Institution Study.","authors":"Wonguen Jung, Jun Woo Lee, Jeongshin An, Kyubo Kim","doi":"10.4048/jbc.2026.0050","DOIUrl":"10.4048/jbc.2026.0050","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated long-term postoperative outcomes and complications after breast-conserving surgery (BCS) with acellular dermal matrix (ADM) insertion.</p><p><strong>Methods: </strong>We retrospectively reviewed the data of patients treated between July 2015 and August 2021. Patients who did not undergo postoperative follow-up were excluded. Clinical characteristics, treatment information, and postoperative complications were collected from the electronic medical records. Complications were classified as major (requiring hospitalization or surgical intervention) or minor (manageable in an outpatient setting). ADM removals were categorized as early (≤ 6 months postoperatively) or delayed (> 6 months).</p><p><strong>Results: </strong>Among the 236 patients (median follow-up, 71.7 months), complications occurred in 119 (50.4%): 22 major (9.3%) and 97 minor (41.1%). Infection was the most common major complication (13/22, 59.2%), whereas seroma was the predominant minor complication (87/97, 89.7%). In univariate analysis, no clinicopathological or treatment-related factors were associated with major complications. ADM removal was performed in 28 patients (11.9%), including nine with local recurrence and 19 unrelated to recurrence (8.1%). Among the 19 nonrecurrent removals, 13 (68.4%) occurred > 6 months after surgery, most commonly due to infection (12/19, 63.2%).</p><p><strong>Conclusion: </strong>Complications after BCS with ADM insertion were common during the long-term follow-up. The 9.3% major complication rate and 8.1% reoperation rate for ADM removal are not negligible. These findings highlight the need for careful patient selection and long-term surveillance of patients undergoing BCS with ADM insertion.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"376-388"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Effectiveness of Adjuvant Endocrine Therapy According to Menopausal Status, Body Mass Index, and Molecular Subtype in Hormone Receptor-Positive Breast Cancer.","authors":"Jung Hun Koh, Youjin Hong, Eun Ji Sim, Soseul Sung, Woojin Lim, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Sue K Park","doi":"10.4048/jbc.2025.0109","DOIUrl":"10.4048/jbc.2025.0109","url":null,"abstract":"<p><p>The effectiveness of adjuvant endocrine therapy for hormone receptor-positive (HR+) breast cancer (BC) varies according to menopausal status, body mass index (BMI), and tumor biology. We evaluated the association between selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and BC-specific mortality according to menopausal status, BMI, and molecular subtype in a nationwide Korean cohort. We analyzed data from 31,030 patients with HR+ BC who were registered in the Korean Breast Cancer Society Registry, diagnosed between 2000 and 2008, and followed through 2013. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for BC-specific mortality after adjusting for demographic and clinical factors. Of the 31,030 patients, 19,634 received SERM therapy, and 3,354 received AI therapy. SERM use was associated with lower BC-specific mortality in premenopausal women (HR, 0.75; 95% CI, 0.63-0.91), whereas AI therapy was more strongly associated with lower BC-specific mortality among postmenopausal women (HR, 0.76; 95% CI, 0.61-0.94). Lower BC-specific mortality was observed among patients with a BMI ≥ 23 kg/m² who received SERM (HR, 0.84; 95% CI, 0.72-0.98) or AI therapy (HR, 0.78; 95% CI, 0.62-0.99). The strongest association with lower BC-specific mortality was observed in postmenopausal women with luminal B tumors (HR, 0.59; 95% CI, 0.42-0.83). The association between adjuvant endocrine therapy and BC-specific mortality differed according to menopausal status, BMI, and molecular subtype. These findings suggest that menopausal status, BMI, and molecular subtype are important considerations when evaluating endocrine treatment strategies.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"29 4","pages":"389-394"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Outcomes of Slowly Proliferating Luminal A-like Invasive Lobular Carcinoma Versus Invasive Carcinoma of No Special Type.","authors":"Dahn Byun, Ji Won Yoo, Jihoon Lee, Ki Beom Kim, Ki Jo Kim, Seungah Lee, Doyoun Woen, Su Min Lee, Kawon Oh, Cho Eun Lee, Woong Ki Park, Jai Min Ryu, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee","doi":"10.4048/jbc.2026.0018","DOIUrl":"10.4048/jbc.2026.0018","url":null,"abstract":"<p><strong>Purpose: </strong>Long-term outcome comparisons between invasive lobular carcinoma (ILC) and invasive carcinoma of no special type (NST, historically referred to as invasive ductal carcinoma) remain inconsistent, particularly in patients with low-proliferative hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) disease. This study evaluated the long-term outcomes of ILC and NST in a pathologically defined, low-proliferative, HR+/HER2- (luminal A-like) cohort.</p><p><strong>Methods: </strong>This retrospective, single-institution study included patients with HR+/HER2- breast cancer and Ki-67 ≤ 20% who underwent surgery between 2008 and 2015. Patients with mixed histopathology, those who underwent palliative surgery, or those who received neoadjuvant chemotherapy were excluded. Survival was analyzed using the Kaplan-Meier method and multivariable Cox regression. A secondary 24-month landmark analysis included patients who were alive, disease-free, under observation, and receiving endocrine therapy 24 months after surgery.</p><p><strong>Results: </strong>Among 3,439 patients, 3,156 had NST and 283 had ILC. Compared with NST, ILC was associated with a higher rate of synchronous bilateral breast cancer, a more advanced pathological stage, and a lower nuclear grade. In the comprehensive cohort, breast cancer-specific survival did not differ significantly (log-rank <i>p =</i> 0.081), whereas disease-free survival (DFS) and distant metastasis-free survival (DMFS) were worse in patients with ILC (log-rank <i>p <</i> 0.001 and <i>p =</i> 0.005, respectively). After adjustment for measured clinicopathological factors, these differences were no longer statistically significant (DFS: adjusted hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.91-1.79; <i>p =</i> 0.164; DMFS: adjusted HR, 1.38; 95% CI, 0.83-2.30; <i>p =</i> 0.210). Detailed biomarker analyses showed similarly high estrogen receptor expression in both groups and lower exact Ki-67 values in ILC. The 24-month landmark analysis revealed the same overall pattern.</p><p><strong>Conclusion: </strong>In this low-proliferative HR+/HER2- cohort, ILC showed less favorable unadjusted long-term DFS and DMFS than NST, but these differences were attenuated and were no longer statistically significant after adjustment for measured clinicopathological characteristics.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"354-363"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy-Related Toxicity and Preoperative Physiologic Reserve as Risk Markers for Complications After Immediate Breast Reconstruction.","authors":"Jaemin Lee, Jihyun Kim, Hyung-Chul Lee, Seung Pil Jung, Jae-Ho Chung, Eul-Sik Yoon","doi":"10.4048/jbc.2026.0035","DOIUrl":"10.4048/jbc.2026.0035","url":null,"abstract":"<p><strong>Purpose: </strong>Despite advances in neoadjuvant chemotherapy (NACT) for breast cancer, surgical outcomes following immediate breast reconstruction (IBR) remain inconsistent, and institutional protocols vary widely. Although patients exhibit heterogeneous physiological responses to chemotherapy, few studies have evaluated treatment-related toxicity as an objective risk marker of postoperative complications. The aim of this study was to assess whether patient-specific responses to NACT can serve as clinically relevant markers of complication risk and guide individualized surgical planning.</p><p><strong>Methods: </strong>A retrospective analysis was conducted of 299 patients who underwent IBR, including 47 who underwent NACT. Chemotherapy-related toxicities and preoperative laboratory values were reviewed to determine the physiological burden. Postoperative complications and delays in the initiation of adjuvant therapy were assessed, and multivariate logistic regression was performed to identify independent factors associated with surgical morbidity.</p><p><strong>Results: </strong>NACT and smoking were significantly associated with an increased risk of complications. NACT was also strongly associated with major wound complications. Patients with hematologic toxicity during NACT or preoperative hypoalbuminemia had substantially higher odds of developing major wound complications. In addition, NACT and diabetes were associated with delayed initiation of adjuvant therapy. NACT was not associated with minor wound complications, such as hematoma or seroma formation.</p><p><strong>Conclusion: </strong>This study suggests that treatment-related toxicity and preoperative physiological reserve may serve as clinically relevant, response-based markers for risk stratification after NACT. This approach provides a conceptual framework for future studies with larger sample sizes and well-controlled designs.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"364-375"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Implications of Calcification and Surgery Type by Estrogen Receptor and HER2 Status in Ductal Carcinoma <i>In Situ</i>: Single-Center Study.","authors":"Je Hyun Chin, Jin Ah Lee, Dooreh Kim, Young Joo Lee, Chang Ik Yoon, Woo-Chan Park, Soo Youn Bae","doi":"10.4048/jbc.2025.0295","DOIUrl":"10.4048/jbc.2025.0295","url":null,"abstract":"<p><strong>Purpose: </strong>Ductal carcinoma <i>in situ</i> (DCIS) presents a challenge in risk stratification, raising concerns regarding both undertreatment and overtreatment. This study investigated the relationships among estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, clinicopathological features, and recurrence in DCIS, with a particular focus on the prognostic roles of calcification and surgical modality.</p><p><strong>Methods: </strong>A retrospective analysis was conducted in 365 patients who underwent surgery for DCIS at The Catholic University of Korea, Seoul St. Mary's Hospital between 1997 and 2020. Ipsilateral breast tumor recurrence (IBTR) and contralateral breast tumor recurrence (CBTR) were evaluated as the primary and secondary endpoints, respectively. Multivariable Cox models were implemented, incorporating radiotherapy, endocrine therapy, and margin status. 1:1 propensity score matching (PSM) was performed to adjust for selection bias between breast-conserving surgery and mastectomy.</p><p><strong>Results: </strong>ER-negative and HER2-positive DCIS were associated with older age, more frequent calcification, and higher nuclear grade (all <i>p</i> < 0.001). In the multivariable analysis for IBTR, surgical modality (mastectomy: hazard ratio [HR], 0.021; <i>p</i> = 0.014) and margin status (≥ 2 mm: HR, 0.192; <i>p</i> = 0.013) were the only independent predictors. Conversely, the presence of calcification was independently associated with more favorable outcomes for CBTR (HR, 0.103; <i>p</i> = 0.013). Subgroup analysis revealed that calcification was significantly associated with improved CBTR-free survival, particularly in the estrogen receptor-positive (ER+) cohort (<i>p</i> = 0.010). PSM analysis confirmed that mastectomy significantly reduced IBTR risk (<i>p</i> = 0.038) but was not significantly associated with CBTR risk (<i>p</i> = 0.246).</p><p><strong>Conclusion: </strong>Calcification and surgical modality demonstrated divergent prognostic implications for IBTR and CBTR according to molecular subtype. Although calcification is traditionally considered a high-risk feature prevalent in aggressive subtypes, its presence was associated with favorable contralateral events in ER+ DCIS. These findings emphasize the importance of integrating molecular markers with clinical features to support more personalized approaches to DCIS management.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"324-338"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}